- Home
- SNSE vs CODX Comparison
SNSE vs CODX Comparison
Compare SNSE & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNSE
- CODX
- Stock Information
- Founded
- SNSE 2005
- CODX 2013
- Country
- SNSE United States
- CODX United States
- Employees
- SNSE N/A
- CODX N/A
- Industry
- SNSE Biotechnology: Pharmaceutical Preparations
- CODX Medical/Dental Instruments
- Sector
- SNSE Health Care
- CODX Health Care
- Exchange
- SNSE Nasdaq
- CODX Nasdaq
- Market Cap
- SNSE 10.2M
- CODX 9.8M
- IPO Year
- SNSE 2021
- CODX 2017
- Fundamental
- Price
- SNSE $8.81
- CODX $0.31
- Analyst Decision
- SNSE Strong Buy
- CODX Buy
- Analyst Count
- SNSE 4
- CODX 2
- Target Price
- SNSE $72.50
- CODX $5.50
- AVG Volume (30 Days)
- SNSE 16.6K
- CODX 5.2M
- Earning Date
- SNSE 08-05-2025
- CODX 08-14-2025
- Dividend Yield
- SNSE N/A
- CODX N/A
- EPS Growth
- SNSE N/A
- CODX N/A
- EPS
- SNSE N/A
- CODX N/A
- Revenue
- SNSE N/A
- CODX $1,003,653.00
- Revenue This Year
- SNSE N/A
- CODX N/A
- Revenue Next Year
- SNSE N/A
- CODX $31.58
- P/E Ratio
- SNSE N/A
- CODX N/A
- Revenue Growth
- SNSE N/A
- CODX N/A
- 52 Week Low
- SNSE $5.00
- CODX $0.23
- 52 Week High
- SNSE $17.40
- CODX $1.58
- Technical
- Relative Strength Index (RSI)
- SNSE 58.00
- CODX 53.94
- Support Level
- SNSE $7.79
- CODX $0.31
- Resistance Level
- SNSE $8.69
- CODX $0.35
- Average True Range (ATR)
- SNSE 0.73
- CODX 0.04
- MACD
- SNSE 0.08
- CODX 0.00
- Stochastic Oscillator
- SNSE 79.72
- CODX 35.36
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.